Abbott Laboratories
May 12, 2020
Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott’s COVID-19 diagnostic kit
MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...
Read More...
Feb 21, 2020
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players
The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medical devices. There is a conspicuous disparity in the economic prowess across the countries, but most of them have shown r...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
